IP Library Granted Patent US 8,332,159
Granted Patent B2
US 8,332,159 · App. 10/546,293 · Granted Dec 11, 2012

Method for enhancing efficacy of preparation of monoclonal antibody

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,332,159
App. No.
10/546,293
Granted
Dec 11, 2012
Kind
B2
Abstract

A method of enhancing the efficacy of a monoclonal antibody preparation wherein antigens from patients are tested for their reactivity with the antibody. An amino acid sequence of an expressed protein is deuced from a nucleotide sequence determined by isolation and analysis of a target molecule gene in a biopsy from a patient. This is compared with the previously determined amino acid sequence recognized by the monoclonal antibody preparation in order to assess the fitness of patients for administration of the monoclonal antibody preparation.

Claims (6)

1. A method for enhancing the efficacy of a monoclonal antibody preparation, wherein said monoclonal antibody is an antibody recognizing the V3 region of the envelope glycoprotein gp120 of human immunodeficiency virus type1 (HIV-1), the method comprising:

a. isolating a nucleotide sequence of a gene of a target molecule from a patient and deducing the amino acid sequence encoded by the nucleotide sequence;

b. comparing the deduced amino acid sequence with a reference amino acid sequence having a specific epitope recognized by a monoclonal antibody comprised by said monoclonal antibody preparation to determine if the deduced amino acid sequence shares the specific epitope with the reference amino acid sequence to determine if the monoclonal antibody will recognize the deduced amino acid sequence; and

c. administering the monoclonal antibody preparation to patients in which the deduced amino acid sequence shares a specific epitope with the reference amino acid sequence so that the monoclonal antibody can recognize the deduced amino acid sequence.

2. The method according to claim 1 , wherein comparing the deduced amino acid sequence and the reference amino acid sequence is conducted using as an index the binding of said monoclonal antibody to a peptide or an expressed protein having the deduced amino acid sequence and/or biological activities of said monoclonal antibody.

3. The method according to claim 1 , wherein the reference amino acid sequence of HIV-1 is selected from the group consisting of IGPARAF (SEQ ID NO:5), IGPGRSF (SEQ ID NO:6), IGPGRAL (SEQ ID NO:7), IGPGRTF (SEQ ID NO:8), IGPGRAI (SEQ ID NO:9), VGPGRAL (SEQ ID NO:10), and IGPGRAF (SEQ ID NO:11).

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2020
From: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: KM BIOLOGICS CO., LTD.
Reel/Frame 051520/0971 →
CHANGE OF ADDRESS OF ASSIGNEE Recorded Apr 15, 2019
From: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 050169/0778 →
CHANGE OF NAME Recorded Jan 16, 2013
From: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 029636/0944 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2006
From: MURAKAMI, TOSHIO; HIGUCHI, HIROFUMI; MAKIZUMI, KEIICHI; MAEDA, TOSHIHIRO; MIZOKAMI, HIROSHI
To: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 018238/0302 →